Does the biotech sector in Spain need to concentrate?

Integral service around a transaction
BY : Diego GutiérrezFebruary Fri, 2015
biotechnology in Spain2014 has been a good year for the biotechnology sector in Spain, mainly due to the improvement in public-private collaboration that is being consolidated in the sector. A number of projects have been carried out acquisitions and mergers and new biotech-focused venture capital funds have emerged.


Spanish biotechnology moves towards concentration

One of the challenges facing the Spanish biotechnology sector is to tackle its atomisation and reach a critical dimension for its growth, mainly international. There are currently around 600 companies, most of them small and medium-sized, whose main activity is biotechnology, which makes their visibility very difficult.

Although it is true that in 2014 several acquisitions were made precisely for this purpose, such as the purchase of Basque  Biophenix, which develops drug screening by Bionaturis, developing biologic medicines, the acquisition of Kiro-Robotics by the giant Grifols or the purchase you have made Natraceutical of the laboratory Reig Jofrea French laboratory with a presence in Europe and the USA. In addition, in 2015 it has also announced the purchase of the French company Trophos 120m from Roche, to which a further €350m could be added depending on milestones. Trophos has a proprietary molecule, TRO19622, which is being investigated in patients with spinal muscular atrophy (SMA), 

BioSpain 2014 was an important forum for doing business, with more than 200 exhibitors and 50 investors, 80 percent of them international.

"The pharmaceutical sector is moving towards the consolidation of a map made up of fewer and larger laboratories", says Diego Gutiérrez, partner at Abra-Invest.

Other challenges for 2015

Among the challenges for 2015 are the need for international investors in Spanish companies, which will allow us to compete with the big companies on a global level. This year international investments have already been made in Spain, such as the €3M investment of the Japanese multinational Yamada BeeFarm 3 in the Spanish company Life Length. 

Another challenge is to alleviate public indebtedness in the biotech sector and to take measures to support SMEs to overcome the crisis.

 Other posts that may interest you

New developments in biotech funds in Spain (En-2015)

Juan Diego Cuenca, partner of Abra-invest, analyses the biotechnology sector on Gestionaradio

M&A deals in biotech companies in Spain are on the rise

The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?